Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,200 DKK | +0.84% | -0.84% | -9.79% |
Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
Feb. 21 | Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). | CI |
Sales 2021 | 36.19 250.67 | Sales 2022 | - | Capitalization | 31.07M 215M |
---|---|---|---|---|---|
Net income 2021 | -627M -4.34B | Net income 2022 | 26M 180M | EV / Sales 2021 | 14,850,643 x |
Net cash position 2021 | 62.29M 431M | Net cash position 2022 | 42.46M 294M | EV / Sales 2022 | - |
P/E ratio 2021 |
-0.96
x | P/E ratio 2022 |
1.19
x | Employees | 1 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 59.56% |
1 day | +0.84% | ||
1 week | -0.84% | ||
Current month | -5.87% | ||
1 month | -6.25% | ||
3 months | -11.78% | ||
6 months | +14.27% | ||
Current year | -9.79% |
Managers | Title | Age | Since |
---|---|---|---|
Jakob Bendtsen
CEO | Chief Executive Officer | 46 | 23-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jakob Have
BRD | Director/Board Member | 43 | 23-05-16 |
Chairman | 53 | 23-05-16 | |
Jakob Bendtsen
CEO | Chief Executive Officer | 46 | 23-05-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 1,200 | +0.84% | 40 |
24-03-26 | 1,190 | +0.03% | 38 |
24-03-25 | 1,189 | -0.88% | 70 |
24-03-22 | 1,200 | -0.83% | 44 |
24-03-21 | 1,210 | +3.42% | 36 |
Delayed Quote Nasdaq Copenhagen, March 27, 2024 at 11:35 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-9.79% | 6.14M | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |